Brian O Mahony/X
Sep 13, 2025, 13:34
Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared a post on X:
“Nugent BIC2025 presents 5 year data on valoctocogene roxaparvovec (Roctavian) GENE R-8 1 trial.
128 of 134 participants completed the trial. Using chromogenic assay at 5 years, mean FVIII 13.7, median 6.2 IU/dl 1/3”
Stay informed with Hemostasis Today.
-
Mar 19, 2026, 18:29Rameez Ashraff: Have You Noticed Neutrophil Inclusions in a Thrombocytopenia Smear?
-
Mar 19, 2026, 18:07Leonardo Roever: A Consensus Framework for Biomarker Research and Clinical Translation in Stroke
-
Mar 19, 2026, 17:49Matteo Foschi: Breaktrough Stroke on Oral Anticoaugulants for Atrial Fibrillation
-
Mar 19, 2026, 17:30UK Haemophilia Society Continues to Empower Individuals and Families Through Advocacy, Education, and Community Support – WFH
-
Mar 19, 2026, 17:20Dimitrios Nikas: Stroke During TAVI Procedures Still Remains Noticeable High
-
Mar 19, 2026, 17:14Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs
-
Mar 19, 2026, 17:03How Personal Experiences Can Support Self‑Advocacy and Help Improve Healthcare Outcomes – Hemophilia Alliance
-
Mar 19, 2026, 16:54X. Long Zheng: Unpacking the Real-World Challenges of ADAMTS13 on ISTH Pulse Podcast
-
Mar 19, 2026, 16:50Zain Khalpey: Predictive Imaging and AI in Aortic Dissection Risk Assessment